The objective of CABA-HFPEF is to test whether catheter ablation (CA) for atrial fibrillation (AF) can prevent adverse cardiovascular outcomes in patients with heart failure with preserved (HFpEF) or mildly reduced ejection fraction (HFmrEF).
Age ≥18 years
Signed written informed consent
Clinical evidence of symptomatic heart failure (NYHA Class II-III)
Paroxysmal or persistent atrial fibrillation (less than 24 months after first diagnosis, documented at least on one 12-lead ECG)
Patient is unable or unwilling to provide infomed consent
Patient is not suitable for rhythm control of AF
Previous left atrial CA or surgical therapy of AF
Acutely decompensated HF, NYHA IV (patients can be enrolled after stabilization)
Charite University, Berlin, Germany
Lead sponsor
Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)
Collaborator
Kompetenznetz Vorhofflimmern e.V. (AFNET)
Collaborator
Boston Scientific Corporation
Collaborator